Company profile: Qu Biologics
1.1 - Company Overview
Company description
- Provider of site specific immunomodulators (SSIs) that restore innate immune function in targeted organs to treat and prevent cancer, chronic inflammatory diseases, and infections. Portfolio includes QBECO (inactivated E. coli; GI; Crohn's/ulcerative colitis), QBKPN (inactivated K. pneumoniae; lungs; lung cancer/respiratory infections), and QBSAU (inactivated S. aureus; skin/soft tissue/bone), with RESILIENCE and PERIOP-06 clinical studies.
Products and services
- QBECO SSI: A pathogen-derived immunomodulator from inactivated E. coli that targets the gastrointestinal tract to restore innate immune function, treating Crohn's disease, ulcerative colitis, and dysfunction in related organs
- QBKPN SSI: An organ-targeted immunomodulator derived from inactivated K. pneumoniae that activates lung and respiratory tract innate immunity to address lung cancer and reduce respiratory infections
- Site Specific Immunomodulators (SSIs): A modular platform of immunomodulators that restore innate immune function to treat and prevent cancer, chronic inflammatory diseases, and infections in gastrointestinal, pulmonary, skin/soft tissue, and bone organs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Qu Biologics
Arch Oncology
HQ: United States
Website
- Description: Provider of venture-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Oncology company profile →
Ab Initio Biotherapeutics
HQ: United States
Website
- Description: Provider of antigen discovery and antibody generation solutions using a proprietary platform targeting multi-transmembrane proteins such as GPCRs, supporting therapeutics for neurological, cardiovascular, endocrine and gastrointestinal disorders; offerings include antibody optimization, single B-cell screening of immune repertoires, the OmniAb Discovery Platform, OmniRat and OmniMouse with high-throughput screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ab Initio Biotherapeutics company profile →
Be Bio
HQ: United States
Website
- Description: Provider of engineered B cell medicines for serious genetic diseases, including BE-101 to produce active and sustained Factor IX for Hemophilia B. Offers BCMs engineered to produce highly active and sustained antitumor biologics for cancer, and BCMs designed to produce therapeutic proteins for genetic and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Be Bio company profile →
Realm Therapeutics
HQ: United States
Website
- Description: Provider of proprietary immunomodulatory technology and clinical-stage biopharmaceutical drug development focused on small molecule therapies for inflammatory diseases, leveraging formulations to protect and improve the health of adults and children.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Realm Therapeutics company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Qu Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Qu Biologics
2.2 - Growth funds investing in similar companies to Qu Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Qu Biologics
4.2 - Public trading comparable groups for Qu Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →